Drug-funding agency Pharmac will not review its decision to drop the subsidy for its popular asthma inhaler Ventolin, saying a study that found its Salamol replacement (which Pharmac now subsidises) to be less effective had "many, many faults".
Pharmac unmoved on Ventolin subsidy
By
Quick Read
AdvertisementAdvertise with NZME.
AdvertisementAdvertise with NZME.